Funding opportunities

ES-Derived Cells for the Treatment of Alzheimer's Disease

Funding Type: 
New Faculty I
Grant Number: 
RN1-00538-A
Principle Investigator: 
Funds requested: 
$2 120 833
Funding Recommendations: 
Recommended if funds allow
Grant approved: 
Yes
Public Abstract: 
Alzheimer’s disease is the most common cause of dementia in the elderly, affecting over 5 million people in the US alone. Boosting immune responses to beta-Amyloid (Aβ) has proven beneficial in mouse models and Alzheimer’s disease (AD) patients. Vaccinating Alzheimer’s mice with Aβ improves cognitive performance and lessens pathological features within the brain, such as Aβ plaque loads. However, human trials with direct Aβ vaccination had to be halted to brain inflammation in some patients. We have demonstrated that T cell immunotherapy also provides cognitive benefits in a mouse model for Alzheimer’s disease, and without any detectable brain inflammation. Translating this approach into a clinical setting requires that we first develop a method to stimulate the proliferation of Aβ-specific T cells without triggering generalized inflammatory response, as happens with vaccinations. Adaptive immune responses are provided by T cells and B cells, which are regulated by the innate immune system through antigen presenting cells, such as mature dendritic cells. We propose to leverage the power of embryonic stem (ES) cells by engineering dendritic cells that express a recombinant transgene that will specifically activate Aβ-specific T cells. We will test the effectiveness of this targeted stimulation strategy using real human T cells. If successful, this approach could provide a direct method to activate beneficial immune responses that may improve cognitive decline in Alzheimer’s disease.
Statement of Benefit to California: 
Alzheimer’s disease is the most common cause of dementia in the elderly, affecting more than 5 million people in the US. In addition to being home to more than 1 in 8 Americans, California is a retirement destination so a proportionately higher percentage of our residents are afflicted with Alzheimer’s disease. It has been estimated that the number of Alzheimer’s patients in the US will grow to 13 million by 2050, so Alzheimer’s disease is a pending health care crisis. Greater still is the emotional toll that Alzheimer’s disease takes on it’s patients, their families and loved one. Currently, there is no effective treatment or cure for Alzheimer’s disease. The research proposed here builds on more than 7 years of work showing that the body’s own immune responses keep Alzheimer’s in check in young and unaffected individuals, but deficiencies in T cell responses to beta-amyloid peptide facilitate disease progression. We have shown that boosting a very specific T cell immune response can provide cognitive and other benefits in mouse models for Alzheimer’s disease. Here we propose to use stem cell research to propel these findings into the clinical domain. This research may provide an effective therapeutic approach to treating and/or preventing Alzheimer’s disease, which will alleviate some of the financial burden caused by this disease and free those health care dollars to be spent for the well-being of all Californians.
Review Summary: 
SYNOPSIS: The applicant has previously shown that beta amyloid - specific T cell immunotherapy can provide beneficial effects in a mouse model for Alzheimer's disease (AD). In more recent preliminary studies, the PI has shown that the beneficial effects of these T cells are associated with a subclass of non-inflammatory Th2 T cells. The research proposed here builds upon these previous and preliminary studies. The overall objective of the study plan is to develop rational protocols using for the production of beta amyloid specific Th2 T cells by using ES stem cell technology to produce beta amyloid (Aβ) presenting dendritic cells to specifically amplify the desired beta amyloid specific T cell population. STRENGTHS AND WEAKNESSES OF THE RESEARCH PLAN: The overarching goal of this proposal is to target proliferation of Aβ-specific T cells using recombinant fusion proteins containing fragments of Aβ 1-42. The applicant has shown that an infusion of Aβ-specific immune T-cells from normal donor mice significantly improved cognitive performance of APP transgenic mice. To bring this finding to the clinical stage, the applicant is proposing to produce CD4+ T cells that recognize Aβ by exposing T-cells isolated from adult donors to dendritic cells differentiated from ES cells transfected with Aβ-MHC2 fusion gene. The study plan unfolds in three phases: The first specific aim is to create a series of MHC class II/amyloid beta fusion constructs in lentivirus expression vectors utilizing different MHC class II haplotypes and different residues of Aβ 1-42. Lentiviruses derived from these vectors will be used to infect human embryonic stem cells and screened for amyloid beta fusion protein expression. The second specific aim is to differentiate human ES cells down through the myeloid lineage to attain dendritic cells that express these amyloid beta fusion constructs. Several different routes towards production of dendritic cells are proposed. Ideally, dendritic cells would be isolated from the ES cells differentiated along the lymphoid lineage; however, at the present time, lymphoid differentiation from ES cells is difficult. Accordingly, the PI proposes to obtain dendritic cells from differentiation of ES cells through the myeloid lineage. However, differentiation of ES cell could be affected by the transfection of Aβ-MHC2 fusion gene and the differentiation conditions to produce dendritic cells from ES cells are not fully established. Thus, the applicant needs to show at least in the preliminary study that he can produce dendritic cells from ES cells. In the third and final stage of research, the PI will use the antigen presenting dendritic cells to activate T cells obtained from organ donors. Plans for obtaining the spleens from six anonymous organ donors at nearby hospitals have been put into place. The reviewers gave this proposal high marks for novelty, innovation and potential scientific and clinical impact, but noted, as did the applicant, that the proposal is high risk. The study plan is carefully considered. The study plan is linear, logical and easy to read. The applicant should be complemented on his well-done and helpful cartoon which pictorially illustrated the three specific aims that will be investigated Potential problems have been recognized and alternative strategies have been proposed wherever possible. QUALIFICATIONS AND POTENTIAL OF THE PRINCIPAL INVESTIGATOR: Dr. Ethel deceived his Bachelor's and Ph.D. from the University of British Columbia and then embarked on a nine year series of postdoctoral training experiences that took him from Germany to the Scripps Resarch Institute, to the Burnham Institute and finally to the La Jolla Institute for Allergy and Immunology. In 2002 he joined the faculty of UC Riverside as an Assistant Professor of Biomedical Sciences. He cites a total of 19 peer-reviewed research publications but the bulk of these papers have appeared in lower tier specialist journals. The PI appears to have many of the skills needed to do this work, although with very limited experience with ES cells. (He has experience with mouse ES cell culture in neurosphere production.) He acknowledges that he has had a problem focusing his research in the past, but now it appears that AD is the major thrust. It is hard to know just how well set up his lab is to do the work; one reviewer was concerned that there was no experience to produce blood cells on the research team. The PI seems to be working on his own with no named collaborators and with no one in particular at UC Riverside. The applicant has provided a career development plan but the plan is rather worrisome. His scientific interests seem unrealistically broad (Alzheimer's disease, Parkinson's disease, mental retardation, autism). There are no concrete plans for advisory committees, mentorship etc. INSTITUTIONAL COMMITMENT TO PRINCIPAL INVESTIGATOR: A letter from the Vice Chancellor for Research at UC Riverside states that Dr. Ethel has a "significant" allocation of research space and equipment and that roughly 75% of his time might be available for research. The Vice Chancellor notes that the normal expectation is that assistant professors will receive promotion to the rank of tenured associate professor within five to seven years. Dr Ethel is currently in year five of his appointment at Assistant Professor. While UC-Riverside appears to want to get into the business of stem cells and perhaps ES cells more specifically, the commitment to Dr. Ethell seems somewhat weak and generic. There is no formal mentoring plan presented. DISCUSSION: The reviewers agreed that the proposal was lucid, articulate, and well-written. The applicant was however, not exceptional in that he has not been highly productive and has shown a lack of focus over the course of his career. The institutional environment is OK, but the PI has been there for 5 years, and at the institution it is up or out in 7 years. The institutional commitment is modest, and no formal mentoring plan was indicated for the PI. The major risk of the research proposal is in the differentiation of ESC to dendritic cells (DCs). If this can't be accomplished, then the proposal can't be done. PROGRAMMATIC DISCUSSION: A motion was made to move this application into Tier 2 – Recommended for Funding, If Funds Are Available. Applicant is mediocre on paper, but this person may be well-positioned to do what is proposed. Although his career has been lengthy and not particularly productive (a panelist said that at least one advisor is known to be difficult), it has been linear in progress. This is essentially an application on a clinically relevant target (AD) from a well-trained immunologist. Panelists also noted that the stem cell program at the institution is developing; there is increasing expertise in stem cell science. There was much discussion about whether it is possible to get DCs from hESC. The panel noted that AD was an important target for stem cells and that this was considered a lucid, well reasoned, albeit risky proposal. The motion to move this application into Tier 2 passed.
Conflicts: 

© 2013 California Institute for Regenerative Medicine